Oral retinoids, isotretinoin (Accutane) and etretinate, uniquely effective in the treatment for severe cystic and keratinization disorders, are potent human teratogens.
Synonyms and Related Disorders
Isotretinoin embryopathy
Genetics/Basic Defects
- 1.
Synthetic retinoids (isotretinoin, etretinate, acitretin)
- a.
Closely resemble naturally occurring vitamin A, which is essential for the maintenance of visual and reproductive function and for proliferation and differentiation of epithelial tissues
- b.
Isotretinoin and etretinate
- i.
Released in the United States and Europe in 1982
- ii.
Isotretinoin: uniquely effective in severe cystic acne
- iii.
Etretinate (and acitretin): uniquely effective in severe psoriasis and other keratinization disorders which proved recalcitrant to all other therapies, account for their availability on prescription despite their teratogenicity
- i.
- c.
Acitretin released later to replace etretinate as it is more rapidly eliminated from the body
...
- a.
This is a preview of subscription content, log in via an institution to check access.
References
Abroms, L., Maibach, E., Lyon-Daniel, K., et al. (2006). What is the best approach to reducing birth defects associated with Isotretinoin? PLoS Medicine, 3, e483.
Atanackovic, G., & Koren, G. (1999a). Fetal exposure to oral isotretinoin: Failure to comply with the Pregnancy Prevention Program. Canadian Medical Association Journal, 160, 1719–1720.
Atanackovic, G., & Koren, G. (1999b). Young women taking isotretinoin still conceive. Role of physicians in preventing disaster. Canadian Family Physician, 45, 289–292.
Braun, J. T., Franciosi, R. A., Mastri, A. R., et al. (1984). Isotretinoin dysmorphic syndrome. Lancet, 1, 506–507.
Brinker, A., Trontell, A., & Beitz, J. (2002). Pregnancy and pregnancy rates in association with isotretinoin (Accutane). Journal of the American Academy of Dermatology, 47, 798–799.
Chan, A., Hanna, M., Abbott, M., et al. (1996). Oral retinoids and pregnancy. The Medical Journal of Australia, 165, 164–167.
Crijns, H. J. M. J., Staus, S. M., Gispen-de Wied, C. H., et al. (2011). Compliance with pregnancy prevention programs of isotretinoin in Europe: A systemic review. British Journal of Dermatology, 164, 238–244.
Dai, W. S., Hsu, M. A., & Itri, L. M. (1989). Safety of pregnancy after discontinuation of isotretinoin. Archives of Dermatology, 125, 362–365.
Dai, W. S., LaBraico, J. M., & Stern, R. S. (1992). Epidemiology of isotretinoin exposure during pregnancy. Journal of the American Academy of Dermatology, 26, 599–606.
de la Cruz, E., Sun, S., Vangvanichyakorn, K., et al. (1984). Multiple congenital malformations associated with maternal isotretinoin therapy. Pediatrics, 74, 428–430.
Ellis, C. N., & Krach, K. J. (2001). Uses and complications of isotretinoin therapy. Journal of the American Academy of Dermatology, 45, S150–S157.
Fernhoff, P. M., & Lammer, E. J. (1984). Craniofacial features of isotretinoin embryopathy. Journal of Pediatrics, 105, 595–597.
Goldsmith, L. A., Bolognia, J. L., Callen, J. P., et al. (2004). American Academy of Dermatology Consensus Conference on the safe and optimal use of isotretinoin: Summary and recommendations. Journal of the American Academy of Dermatology, 50, 900–906.
Hansen, R. C. (1985). Accutane (isotretinoin) revisited: Severe birth defects from acne therapy. Arizona Medicine, 42, 363–365.
Holmes, S. C., Bankowska, U., & Mackie, R. M. (1998). The prescription of isotretinoin to women: Is every precaution taken? British Journal of Dermatology, 138, 450–455.
Jahn, A. F., & Ganti, K. (1987). Major auricular malformations due to Accutane (isotretinoin). Laryngoscope, 97, 832–835.
Jones, K. L., Adams, J., Chambers, C. D., et al. (2001). Isotretinoin and pregnancy. Journal of the American Medical Association, 285, 2079–2081.
Kassis, I., Sunderji, S., & Abdul-Karim, R. (1985). Isotretinoin (Accutane) and pregnancy. Teratology, 32, 145–146.
Koren, G., & Pastuszak, A. (1997). How to ensure fetal safety when mothers use isotretinoin (Accutane). Canadian Family Physician, 43, 216–219.
Lammer, E. J., Schunior, A., Hayes, A. M., et al. (1988). Isotretinoin dose and teratogenicity. Lancet, 2, 503–504.
Lancaster, P. A. (1988). Teratogenicity of isotretinoin. Lancet, 2, 1254–1255.
Mitchell, A. A., & Van Bennekom, C. M. (2003). Accutane and pregnancy. Journal of the American Academy of Dermatology, 49, 1201–1202.
Mitchell, A. A., Van Bennekom, C. M., & Louik, C. (1995). A pregnancy-prevention program in women of childbearing age receiving isotretinoin. The New England Journal of Medicine, 333, 101–106.
Nau, H. (2001). Teratogenicity of isotretinoin revisited: Species variation and the role of all-trans-retinoic acid. Journal of the American Academy of Dermatology, 45, S183–S187.
Pastuszak, A., Koren, G., & Rieder, M. J. (1994). Use of the Retinoid Pregnancy Prevention Program in Canada: Patterns of contraception use in women treated with isotretinoin and etretinate. Reproductive Toxicology, 8, 63–68.
Perlman, S. E., Leach, E. E., Dominguez, L., et al. (2001). Be smart, be safe, be sure. The revised Pregnancy Prevention Program for women on isotretinoin. Journal of Reproductive Medicine, 46, 179–185.
Pochi, P. E., Ceilley, R. I., Coskey, R. J., et al. (1988). Guidelines for prescribing isotretinoin (Accutane) in the treatment of female acne patients of childbearing potential. Acne Subgroup, Task Force on Standards of Care. Journal of the American Academy of Dermatology, 19, 920.
Rappaport, E. B., & Knapp, M. (1989). Isotretinoin embryopathy-a continuing problem. Journal of Clinical Pharmacology, 29, 463–465.
Rizzo, R., Lammer, E. J., Parano, E., et al. (1991). Limb reduction defects in humans associated with prenatal isotretinoin exposure. Teratology, 44, 599–604.
Shear, N. H. (1999). Oral isotretinoin: Prescribers beware. Canadian Medical Association Journal, 160, 1723–1724.
Stashower, M. E. (2003). Pregnancy rates associated with isotretinoin (Accutane) and the FDA. Journal of the American Academy of Dermatology, 49, 1202–1203.
Strauss, J. S., Cunningham, W. J., Leyden, J. J., et al. (1988). Isotretinoin and teratogenicity. Journal of the American Academy of Dermatology, 19, 353–354.
Strauss, J. S., Leyden, J. J., Lucky, A. W., et al. (2001). Safety of a new micronized formulation of isotretinoin in patients with severe recalcitrant nodular acne: A randomized trial comparing micronized isotretinoin with standard isotretinoin. Journal of the American Academy of Dermatology, 45, 196–207.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this entry
Cite this entry
(2012). Retinoid Embryopathy. In: Chen, H. (eds) Atlas of Genetic Diagnosis and Counseling. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-1037-9_201
Download citation
DOI: https://doi.org/10.1007/978-1-4614-1037-9_201
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-1036-2
Online ISBN: 978-1-4614-1037-9
eBook Packages: Biomedical and Life SciencesReference Module Biomedical and Life Sciences